Solomon M, Baum S, Barzilai A, Pavlotsky F, Trau H, Schwartz E
Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1189-92. doi: 10.1111/j.1468-3083.2009.03157.x. Epub 2009 Feb 24.
Cutaneous leishmaniasis is endemic in Israel. Leishmania major is the most prevalent species that cause cutaneous leishmaniasis. Current treatment options are limited and there are few investigations in search of alternative ones.
This study aims to assess our experience with intralesional sodium stibogluconate (SSG) in the treatment of cutaneous leishmaniasis.
A retrospective evaluation for all adult cases of cutaneous leishmaniasis treated by intralesional and intravenous SSG (Pentostam, GlaxoSmithKline) between 2004 and 2006 was performed, for cases referred to a tertiary care university-affiliated medical centre in Israel. Intralesional SSG was injected at 0.5 mL per lesion (50 mg). Treatment was repeated every 2-3 weeks for a total of 12 weeks. Intravenous SSG was administered at a dose of 20 mg/kg for 10-20 days.
Thirty-three cases of cutaneous leishmaniasis were treated with intralesional SSG during the study period. The patients consist of 26 males and 7 females, mostly Israeli military personnel, and there were a total of 93 lesions. Within 3 months from treatment onset, 91% (30/33) had completed healing of the cutaneous lesions after an average of 3 treatments (range 1-6). Side-effects were mild and were mostly pain during injection, with two patients developing mild local site reaction after the injection.
Intralesional SSG treatment is safe, effective and well tolerated with minimal side-effects.
皮肤利什曼病在以色列呈地方性流行。硕大利什曼原虫是引起皮肤利什曼病最常见的种类。目前的治疗选择有限，且很少有研究寻找替代疗法。
本研究旨在评估我们使用病灶内注射葡萄糖酸锑钠（SSG）治疗皮肤利什曼病的经验。
对2004年至2006年间在以色列一家大学附属三级医疗中心就诊的所有接受病灶内和静脉注射SSG（葡酸锑钠，葛兰素史克公司生产）治疗的成年皮肤利什曼病病例进行回顾性评估。病灶内注射SSG的剂量为每病灶0.5 mL（50 mg）。每2 - 3周重复治疗一次，共治疗12周。静脉注射SSG的剂量为20 mg/kg，持续10 - 20天。
在研究期间，33例皮肤利什曼病患者接受了病灶内注射SSG治疗。患者包括26名男性和7名女性，大多数为以色列军人，共有93个病灶。从治疗开始3个月内，91%（30/33）的患者在平均接受3次治疗（范围1 - 6次）后皮肤病变完全愈合。副作用轻微，主要是注射时疼痛，两名患者注射后出现轻度局部反应。
病灶内注射SSG治疗安全、有效，耐受性良好，副作用最小。
